

# Iron Deficiency Anemia: Evaluation and Management

MATTHEW W. SHORT, LTC, MC, USA, and JASON E. DOMAGALSKI, MAJ, MC, USA  
*Madigan Healthcare System, Tacoma, Washington*

Iron deficiency is the most common nutritional disorder worldwide and accounts for approximately one-half of anemia cases. The diagnosis of iron deficiency anemia is confirmed by the findings of low iron stores and a hemoglobin level two standard deviations below normal. Women should be screened during pregnancy, and children screened at one year of age. Supplemental iron may be given initially, followed by further workup if the patient is not responsive to therapy. Men and postmenopausal women should not be screened, but should be evaluated with gastrointestinal endoscopy if diagnosed with iron deficiency anemia. The underlying cause should be treated, and oral iron therapy can be initiated to replenish iron stores. Parenteral therapy may be used in patients who cannot tolerate or absorb oral preparations. (*Am Fam Physician*. 2013;87(2):98-104. Copyright © 2013 American Academy of Family Physicians.)

► **Patient information:**  
A handout on iron deficiency anemia, written by the authors of this article, is available at <http://www.aafp.org/afp/2013/0115/p98-s1.html>. Access to the handout is free and unrestricted.

**I**ron deficiency anemia is diminished red blood cell production due to low iron stores in the body. It is the most common nutritional disorder worldwide and accounts for approximately one-half of anemia cases.<sup>1,2</sup> Iron deficiency anemia can result from inadequate iron intake, decreased iron absorption, increased iron demand, and increased iron loss.<sup>3</sup> Identifying the underlying etiology and administering the appropriate therapy are keys to the evaluation and management of this condition.

## Diagnosis

Diagnosis of iron deficiency anemia requires laboratory-confirmed evidence of anemia, as well as evidence of low iron stores.<sup>4</sup> Anemia is defined as a hemoglobin level two standard deviations below normal for age and sex (*Table 1*).<sup>5</sup>

A complete blood count can be helpful to determine the mean corpuscular volume or red blood cell size. Although iron deficiency is the most common cause of microcytic anemia, up to 40 percent of patients with iron deficiency anemia will have normocytic erythrocytes.<sup>2</sup> As such, iron deficiency should still be considered in all cases of anemia unless the mean corpuscular volume is greater than  $95 \mu\text{m}^3$  (95 fL), because this cutoff has a sensitivity of 97.6 percent.<sup>6</sup> Other

causes of microcytosis include chronic inflammatory states, lead poisoning, thalassemia, and sideroblastic anemia.<sup>1</sup>

The following diagnostic approach is recommended in patients with anemia and is outlined in *Figure 1*.<sup>2,6-11</sup> A serum ferritin level should be obtained in patients with anemia and a mean corpuscular volume less than  $95 \mu\text{m}^3$ . Ferritin reflects iron stores and is the most accurate test to diagnose iron deficiency anemia.<sup>7</sup> Although levels below 15 ng per mL (33.70 pmol per L) are consistent with a diagnosis of iron deficiency anemia, using a cutoff of 30 ng per mL (67.41 pmol per L) improves sensitivity from 25 to 92 percent, and specificity remains high at 98 percent.<sup>8,12</sup> Ferritin is also an acute phase reactant and can be elevated in patients with chronic inflammation or infection. In patients with chronic inflammation, iron deficiency anemia is likely when the ferritin level is less than 50 ng per mL (112.35 pmol per L).<sup>7</sup> Ferritin values greater than or equal to 100 ng per mL (224.70 pmol per L) generally exclude iron deficiency anemia.<sup>9,10</sup>

In patients with no inflammatory states and in whom the ferritin level is indeterminate (31 to 99 ng per mL [69.66 to 222.45 pmol per L]), further tests can be performed to ascertain iron status. Values consistent with iron deficiency include a low serum iron level,

**Table 1. Age-Related Variations in Hemoglobin Level and MCV**

Age	Hemoglobin level (g per dL [g per L])		MCV ( $\mu\text{m}^3$ [fL])	
	Mean	Diagnostic of anemia	Mean	Diagnostic of microcytosis
3 to 6 months	11.5 (115)	9.5 (95)	91 (91)	74 (74)
6 months to 2 years	12.0 (120)	10.5 (105)	78 (78)	70 (70)
2 to 6 years	12.5 (125)	11.5 (115)	81 (81)	75 (75)
6 to 12 years	13.5 (135)	11.5 (115)	86 (86)	77 (77)
12 to 18 years (female)	14.0 (140)	12.0 (120)	90 (90)	78 (78)
12 to 18 years (male)	14.5 (145)	13.0 (130)	88 (88)	78 (78)
20 to 59 years (white men)	NA	13.7 (137)	90 (90)	80 (80)
60 years and older (white men)	NA	13.2 (132)	90	80
20 years and older (white women)	NA	12.2 (122)	90	80
20 to 59 years (black men)	NA	12.9 (129)	90	80
60 years and older (black men)	NA	12.7 (127)	90	80
20 years and older (black women)	NA	11.5 (115)	90	80


MCV = mean corpuscular volume; NA = not available.

Adapted with permission from Van Vranken M. Evaluation of microcytosis. Am Fam Physician. 2010;82(9):1118.

low transferrin saturation, and a high total iron-binding capacity.<sup>2</sup>

Soluble transferrin receptor and erythrocyte protoporphyrin testing, or bone marrow biopsy can be considered if the diagnosis remains unclear.<sup>2</sup> The soluble transferrin receptor level is an indirect measure of erythropoiesis and is increased in patients with iron deficiency anemia.<sup>8</sup> Another benefit of this test is that the soluble transferrin receptor level is unaffected by inflammatory states and can help identify concomitant iron deficiency anemia in patients with anemia of chronic disease.<sup>12</sup> Erythrocyte protoporphyrin is a heme precursor and accumulates in the absence of adequate iron stores.<sup>11</sup> If other tests are indeterminate and suspicion for iron deficiency anemia

### Diagnosis of Iron Deficiency Anemia



**Figure 1.** Algorithm for diagnosis of iron deficiency anemia.

Information from references 2, and 6 through 11.

## Iron Deficiency Anemia

**Table 2. Etiologies of Iron Deficiency Anemia**

Etiology	Prevalence (%)
Abnormal uterine bleeding	20 to 30
Long-term use of aspirin or other nonsteroidal anti-inflammatory drugs	10 to 15
Colonic carcinoma	5 to 10
Angiodysplasia	5
Blood donation	5
Gastric carcinoma	5
Peptic ulcer disease	5
Celiac disease	4 to 6
Gastrectomy	< 5
<i>Helicobacter pylori</i> infection	< 5
Esophagitis	2 to 4
Esophageal carcinoma	1 to 2
Gastric antral vascular ectasia	1 to 2
Small bowel tumors	1 to 2
Hematuria	1
Ampullary carcinoma	< 1
Bacterial overgrowth	< 1
Cameron ulcer (i.e., ulcer in large hiatal hernia)	< 1
Epistaxis	< 1
Intestinal resection	< 1

Information from references 5, 7, 18, and 19.

persists, the absence of stainable iron in a bone marrow biopsy is considered the diagnostic standard.<sup>2</sup>

### Screening

#### MEN AND POSTMENOPAUSAL WOMEN

Asymptomatic men and postmenopausal women should not be screened for iron deficiency anemia. Testing should be performed in patients with signs and symptoms of anemia, and a complete evaluation should be performed if iron deficiency is confirmed.<sup>13</sup>

#### PREGNANT WOMEN

The American Academy of Family Physicians, U.S. Preventive Services Task Force, and Centers for Disease Control and Prevention recommend routine screening of asymptomatic pregnant women for iron deficiency anemia.<sup>4,11,14</sup> The American College of Obstetricians and Gynecologists recommends screening for anemia and implementing iron therapy if iron deficiency anemia is confirmed.<sup>15</sup> The defined values consistent with anemia in pregnancy are hemoglobin levels less than 11 g per dL (110 g per L) in the first or third trimester, or less than 10.5 g per dL (105 g per L) in the second trimester.<sup>16</sup> A

maternal hemoglobin level of less than 6 g per dL (60 g per L) has been associated with poor fetal outcomes, including death.<sup>15</sup>

### CHILDREN

The American Academy of Pediatrics recommends universal hemoglobin screening and evaluation of risk factors for iron deficiency anemia in all children at one year of age.<sup>16</sup> Risk factors include low birth weight, history of prematurity, exposure to lead, exclusive breastfeeding beyond four months of life, and weaning to whole milk and complementary foods without iron-fortified foods.<sup>16</sup> The Centers for Disease Control and Prevention recommends screening children from low-income or newly immigrated families at nine to 12 months of age, and consideration of screening for preterm and low-birth-weight infants before six months of age if they are not given iron-fortified formula.<sup>14</sup> The U.S. Preventive Services Task Force found insufficient evidence for screening in asymptomatic children six to 12 months of age and does not make recommendations for other ages.<sup>4</sup> A meta-analysis showed that infants in whom cord clamping was delayed for up to two minutes after birth had a reduced risk of low iron stores for up to six months.<sup>17</sup> Larger randomized studies that include maternal outcomes are needed before delayed cord clamping can be recommended for general practice.

### Causes

Once iron deficiency anemia is identified, the goal is to determine the underlying etiology. Causes include inadequate iron intake, decreased iron absorption, increased iron demand, and increased iron loss (Table 2).<sup>5,7,18,19</sup>


### Iron Therapy

Premenopausal women with a negative evaluation for abnormal uterine bleeding can be given a trial of iron therapy. In children and pregnant women, iron therapy should be tried initially. Current guidelines recommend empiric treatment in children up to two years of age and in pregnant women with iron deficiency anemia; however, if the hemoglobin level does not increase by 1 g per dL (10 g per L) after one month of therapy in children or does not improve in pregnant women, further evaluation may be indicated.<sup>4,15,16</sup> In pregnant patients, poor compliance or intolerance should be considered, and parenteral iron may produce a better response.<sup>15</sup>

### Evaluation

The evaluation should begin with a thorough history and physical examination to help identify the cause of

## Evaluation of Iron Deficiency Anemia



**Figure 2.** Algorithm for evaluation of iron deficiency anemia. (GI = gastrointestinal.)

Information from references 10, 15, and 17 through 21.

iron deficiency. The history should focus on potential etiologies and may include questions about diet, gastrointestinal (GI) symptoms, history of pica or pagophagia (i.e., compulsive consumption of ice), signs of blood loss (e.g., epistaxis, menorrhagia, melena, hematuria, hematemesis), surgical history (e.g., gastric bypass), and family history of GI malignancy. Patients with iron deficiency anemia are often asymptomatic and have limited findings on examination. Further evaluation should be based on risk factors (Figure 2).<sup>10,15,17-21</sup>

### PREMENOPAUSAL WOMEN

Excessive menstruation is a common cause of iron deficiency anemia in premenopausal women in developed countries; however, a GI source (particularly erosive

lesions in the stomach or esophagus) is present in 6 to 30 percent of cases.<sup>20,22,23</sup> If the gynecologic workup is negative and the patient does not respond to iron therapy, endoscopy should be performed to exclude an occult GI source.<sup>20,22,23</sup>

Excessive or irregular menstrual bleeding affects 9 to 14 percent of all women and can lead to varying degrees of iron deficiency anemia.<sup>24</sup> Etiologies include thyroid disease, uncontrolled diabetes mellitus, polycystic ovary syndrome, coagulopathies, uterine fibroids, endometrial hyperplasia, hyperprolactinemia, and use of antipsychotics or antiepileptics. Initial evaluation includes a history, physical examination, and pregnancy and thyroid-stimulating hormone tests. An endometrial biopsy should be considered in women 35 years and younger who have conditions that could lead to unopposed estrogen exposure, in women older than 35 years who have suspected anovulatory bleeding, and in women with abnormal uterine bleeding that does not respond to medical therapy.<sup>25</sup>

### MEN AND POSTMENOPAUSAL WOMEN

In men and postmenopausal women, GI sources of bleeding should be excluded. Current recommendations support upper and lower endoscopy; however, there are no clear guidelines about which procedure should be performed first or if the second procedure is necessary if a source is found on the first study.<sup>18</sup> Lesions that occur simultaneously in the upper and lower tracts are rare, occurring in only 1 to 9 percent of patients.<sup>18</sup> However, one study showed that

12.2 percent of patients diagnosed with celiac disease and iron deficiency anemia had a secondary source of anemia, including three cases of colon cancer.<sup>26</sup> A study of patients with iron deficiency anemia of unknown etiology in the primary care setting found that 11 percent had newly diagnosed GI cancer.<sup>27</sup> Additionally, a cohort study found that 6 percent of patients older than 50 years and 9 percent of those older than 65 years will be diagnosed with a GI malignancy within two years of a diagnosis of iron deficiency anemia.<sup>28</sup>

Celiac serology should also be considered for all adults presenting with iron deficiency anemia.<sup>18</sup> Upper endoscopy with duodenal biopsies should be performed to confirm the diagnosis after positive serologic testing and to evaluate for additional etiologies.<sup>29</sup>

## Iron Deficiency Anemia

In patients in whom endoscopy may be contraindicated because of procedural risk, radiographic imaging may offer sufficient screening. The sensitivity of computed tomographic colonography for lesions larger than 1 cm is greater than 90 percent.<sup>7</sup> The use of barium enema is less reliable, but may be of use if colonoscopy or computed tomographic colonography is not available.

If initial endoscopy findings are negative and patients with iron deficiency anemia do not respond to iron therapy, repeat upper and lower endoscopy may be justified. In some instances, lesions may not be detected on initial examination (e.g., missed mucosal erosions in a large hiatal hernia, suboptimal preparation for colonoscopy, inadequate biopsy of a suspected lesion).<sup>13</sup> Colonoscopy can fail to diagnose up to 5 percent of colorectal tumors.<sup>13</sup>

Additional evaluation of the small intestine is not necessary unless there is inadequate response to iron therapy, the patient is transfusion dependent, or fecal occult blood testing suggests that the patient has had obscure GI bleeding with the source undiscovered on initial or repeat endoscopy.<sup>30</sup> In these cases, further evaluation with capsule endoscopy should be considered.<sup>30</sup> Enteroscopy is an upper endoscopy procedure using a longer scope to visualize the proximal jejunum; it should be reserved to treat or biopsy lesions identified by capsule endoscopy. This test is a second-line technique for evaluating the small bowel because it is complicated by the level of sedation and duration of procedure.<sup>13</sup> Magnetic resonance imaging enteroclysis, computed tomographic enterography, or barium studies may also be considered, but have a limited ability to identify most small bowel lesions, which are mucosal and flat.<sup>7</sup>

### Treatment


#### UNDERLYING CAUSE

Patients with an underlying condition that causes iron deficiency anemia should be treated or referred to a subspecialist (e.g., gynecologist, gastroenterologist) for definitive treatment.

#### ORAL IRON THERAPY

The dosage of elemental iron required to treat iron deficiency anemia in adults is 120 mg per day for three months; the dosage for children is 3 mg per kg per day, up to 60 mg per day.<sup>1</sup> An increase in hemoglobin of 1 g

## Treatment of Iron Deficiency Anemia



**Figure 3.** Algorithm for treatment of iron deficiency anemia. (CBC = complete blood count.)

Information from references 6, 28, and 31.

per dL after one month of treatment shows an adequate response to treatment and confirms the diagnosis.<sup>16</sup> In adults, therapy should be continued for three months after the anemia is corrected to allow iron stores to become replenished<sup>7</sup> (Figure 3<sup>6,28,31</sup>).

Adherence to oral iron therapy can be a barrier to treatment because of GI adverse effects such as epigastric discomfort, nausea, diarrhea, and constipation. These effects may be reduced when iron is taken with meals, but absorption may decrease by 40 percent.<sup>1</sup> Medications such as proton pump inhibitors and factors that induce gastric acid hyposecretion (e.g., chronic atrophic gastritis, recent gastrectomy or vagotomy) are associated with reduced absorption of dietary iron and iron tablets.<sup>31</sup>

#### PARENTERAL IRON THERAPY

Parenteral therapy may be used in patients who cannot tolerate or absorb oral preparations, such as those who have undergone gastrectomy, gastrojejunostomy, bariatric surgery, or other small bowel surgeries. The most common indications for intravenous therapy include GI effects, worsening symptoms of inflammatory bowel disease, unresolved bleeding, renal failure–induced anemia treated with erythropoietin, and insufficient absorption in patients with celiac disease.<sup>32</sup>

**Table 3. Iron Therapy: Formulations and Dosing**

Form	Formulation	Elemental iron	Adult dosage
<b>Intravenous</b>			
Sodium ferric gluconate (Ferrelecit)	Solution for injection	12.5 mg per mL	Based on weight and amount of desired change in hemoglobin*
Iron dextran	Solution for injection	50 mg per mL	
Iron sucrose	Solution for injection	20 mg per mL	
Ferumoxytol	Solution for injection	30 mg per mL	
<b>Oral</b>			
Ferrous fumarate	324-mg tablet	106 mg	One tablet twice per day
Ferrous gluconate	300-mg tablet	38 mg	One to three tablets two or three times per day
Ferrous sulfate	325-mg tablet	65 mg	One tablet three times per day

\*—Elemental iron (mg) =  $50 \times (0.442 [\text{desired hemoglobin level in g per L} - \text{observed hemoglobin level in g per L}] \times \text{lean body weight} + 0.26 \times \text{lean body weight})$ .<sup>2</sup>

Information from references 2 and 16.

#### SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation	Evidence rating	References
Measurement of the serum ferritin level is the most accurate test to diagnose iron deficiency anemia.	C	6, 7
All pregnant women should be screened for iron deficiency anemia.	C	4, 11, 14
All adult men and postmenopausal women with iron deficiency anemia should be screened for gastrointestinal malignancy.	C	18, 26, 27
Screening serology for celiac disease should be considered for all adults with iron deficiency anemia.	C	18

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <http://www.aafp.org/afpsort.xml>.

Parenteral treatment options are outlined in Table 3.<sup>2,16</sup> Serious adverse effects have occurred in up to 0.7 percent of patients receiving iron dextran, with 31 recorded fatalities reported between 1976 and 1996.<sup>32,33</sup> Iron sucrose and sodium ferric gluconate (Ferrelecit) have greater bioavailability and a lower incidence of life-threatening anaphylaxis compared with iron dextran.<sup>2</sup> Approximately 35 percent of patients receiving iron sucrose have mild adverse effects (e.g., headache, nausea, diarrhea).<sup>7</sup> One small study cited similar adverse effect profiles between intravenous iron dextran and sodium ferric gluconate, with only one serious adverse effect reported in the iron

dextran group.<sup>34</sup> If this finding is duplicated in larger studies, it could support the use of iron dextran over sodium ferric gluconate, because the total dose can be given in one sitting. A newer formulation, ferumoxytol, can be given over five minutes and supplies 510 mg of elemental iron per infusion, allowing for greater amounts of iron in fewer infusions compared with iron sucrose.<sup>2</sup>

#### MONITORING

There are no standard recommendations for follow-up after initiating therapy for iron deficiency anemia; however, one suggested course is to recheck complete blood counts every three months for one year. If hemoglobin and red blood cell indices remain normal, one additional complete blood count should be obtained 12 months later. A more practical approach is to recheck the patient periodically; no further follow-up is necessary if the patient is asymptomatic and the hematocrit level remains normal.<sup>7</sup>

#### BLOOD TRANSFUSION

There is no universally accepted threshold for transfusing packed red blood cells in patients with iron deficiency anemia. Guidelines often specify certain hemoglobin values as indications to transfuse, but the patient's clinical condition and symptoms are an essential part of deciding whether to transfuse.<sup>35</sup> Transfusion is recommended in pregnant women with hemoglobin levels of less than 6 g per dL because of potentially abnormal fetal oxygenation resulting in non-reassuring fetal heart tracings, low amniotic fluid volumes, fetal cerebral vasodilation, and fetal death.<sup>15</sup> If transfusion is performed, two units of packed red blood cells should be given, then the clinical situation should be reassessed to guide further treatment.<sup>35</sup>

**Data Sources:** A PubMed search was completed in Clinical Queries using the key terms iron deficiency and anemia. The search included meta-analyses, randomized controlled trials, controlled trials, and reviews. Searches were also performed using Essential Evidence Plus, the Cochrane database, the National Guideline Clearinghouse database, the Trip Database, DynaMed, and the Agency for Healthcare Research and Quality evidence reports. Search date: January 10, 2012.

The views expressed are those of the authors and do not reflect the official policy of the Department of the Army, the Department of Defense, or the U.S. government.

## The Authors

MATTHEW W. SHORT, LTC, MC, USA, is program director of the transitional year program and the Family Medicine Colonoscopy Fellowship at Madigan Healthcare System, Tacoma, Wash. He is also an associate professor of family medicine at the Uniformed Services University of the Health Sciences, Bethesda, Md., and a clinical assistant professor of family medicine at the University of Washington School of Medicine, Seattle.

JASON E. DOMAGALSKI, MAJ, MC, USA, is a family medicine residency faculty member at Madigan Healthcare System. He is also an assistant professor of family medicine at the Uniformed Services University of the Health Sciences, and a clinical instructor of family medicine at the University of Washington School of Medicine.

Address correspondence to Matthew W. Short, LTC, MC, USA, Madigan Healthcare System, 9040 Jackson Ave., MCHJ-CLF-C, Tacoma, WA 98341-1100. Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations to disclose.

## REFERENCES

1. World Health Organization. *Iron Deficiency Anaemia: Assessment, Prevention, and Control: A Guide for Programme Managers*. Geneva, Switzerland: World Health Organization; 2001.
2. Johnson-Wimbley TD, Graham DY. Diagnosis and management of iron deficiency anemia in the 21st century. *Therap Adv Gastroenterol*. 2011;4(3):177-184.
3. WHO Global Database on Anaemia. *Worldwide Prevalence of Anaemia 1993-2005*. Geneva, Switzerland: World Health Organization; 2008.
4. U.S. Preventive Services Task Force. Screening for iron deficiency anemia, including iron supplementations for children and pregnant women: recommendation statement. *Am Fam Physician*. 2006;74(3):461-464.
5. Van Vranken M. Evaluation of microcytosis. *Am Fam Physician*. 2010;82(9):1117-1122.
6. Ioannou GN, Spector J, Scott K, Rockey DC. Prospective evaluation of a clinical guideline for the diagnosis and management of iron deficiency anemia. *Am J Med*. 2002;113(4):281-287.
7. Goddard AF, James MW, McIntyre AS, Scott BB; British Society of Gastroenterology. Guidelines for the management of iron deficiency anaemia. *Gut*. 2011;60(10):1309-1316.
8. Mast AE, Blinder MA, Gronowski AM, Chumley C, Scott MG. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. *Clin Chem*. 1998;44(1):45-51.
9. Knovich MA, Storey JA, Coffman LG, Torti SV, Torti FM. Ferritin for the clinician. *Blood Rev*. 2009;23(3):95-104.
10. Galloway MJ, Smellie WS. Investigating iron status in microcytic anaemia. *BMJ*. 2006;333(7572):791-793.
11. Assessing the iron status of populations: report of a joint World Health Organization/Centers for Disease Control and Prevention technical consultation on the assessment of iron status at the population level, Geneva, Switzerland, 6-8 April 2004. Geneva: World Health Organization, Centers for Disease Control and Prevention; 2005.
12. Skikne BS, Punnonen K, Caldron PH, et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. *Am J Hematol*. 2011;86(11):923-927.
13. Bermejo F, García-López S. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. *World J Gastroenterol*. 2009;15(37):4638-4643.
14. Centers for Disease Control and Prevention. Recommendations to prevent and control iron deficiency in the United States. *MMWR Recomm Rep*. 1998;47(RR-3):1-29.
15. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 95: anemia in pregnancy. *Obstet Gynecol*. 2008;112(1):201-207.
16. Baker RD, Greer FR; Committee on Nutrition, American Academy of Pediatrics. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children (0-3 years of age). *Pediatrics*. 2010;126(5):1040-1050.
17. Hutton EK, Hassan ES. Late vs early clamping of the umbilical cord in full-term neonates: systematic review and meta-analysis of controlled trials. *JAMA*. 2007;297(11):1241-1252.
18. Liu K, Kaffes AJ. Iron deficiency anaemia: a review of diagnosis, investigation and management. *Eur J Gastroenterol Hepatol*. 2012;24(2):109-116.
19. British Columbia Ministry of Health. Iron deficiency—investigation and management. [http://www.bcguidelines.ca/guideline\\_iron\\_deficiency.html](http://www.bcguidelines.ca/guideline_iron_deficiency.html). Accessed November 13, 2012.
20. Carter D, Maor Y, Bar-Meir S, Avidan B. Prevalence and predictive signs for gastrointestinal lesions in premenopausal women with iron deficiency anemia. *Dig Dis Sci*. 2008;53(12):3138-3144.
21. American College of Obstetricians and Gynecologists Committee on Adolescent Health Care; American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion no. 451: Von Willebrand disease in women. *Obstet Gynecol*. 2009;114(6):1439-1443.
22. Green BT, Rockey DC. Gastrointestinal endoscopic evaluation of premenopausal women with iron deficiency anemia. *J Clin Gastroenterol*. 2004;38(2):104-109.
23. Park DI, Ryu SH, Oh SJ, et al. Significance of endoscopy in asymptomatic premenopausal women with iron deficiency anemia. *Dig Dis Sci*. 2006;51(12):2372-2376.
24. Fraser IS, Langham S, Uhl-Hochgraeber K. Health-related quality of life and economic burden of abnormal uterine bleeding. *Expert Rev Obstet Gynecol*. 2009;4(2):179-189.
25. ACOG Committee on Practice Bulletins—Gynecology, American College of Obstetricians and Gynecologists. ACOG practice bulletin: management of anovulatory bleeding. *Int J Gynaecol Obstet*. 2001;72(3):263-271.
26. Hopper AD, Leeds JS, Hurlstone DP, Hadjivassiliou M, Drew K, Sanders DS. Are lower gastrointestinal investigations necessary in patients with coeliac disease? *Eur J Gastroenterol Hepatol*. 2005;17(6):617-621.
27. Yates JM, Logan EC, Stewart RM. Iron deficiency anaemia in general practice: clinical outcomes over three years and factors influencing diagnostic investigations. *Postgrad Med J*. 2004;80(945):405-410.
28. Ioannou GN, Rockey DC, Bryson CL, Weiss NS. Iron deficiency and gastrointestinal malignancy: a population-based cohort study. *Am J Med*. 2002;113(4):276-280.
29. Lewis NR, Scott BB. Systematic review: the use of serology to exclude or diagnose coeliac disease (a comparison of the endomysial and tissue transglutaminase antibody tests). *Aliment Pharmacol Ther*. 2006;24(1):47-54.
30. Sidhu R, Sanders DS, Morris AJ, McAlindon ME. Guidelines on small bowel enteroscopy and capsule endoscopy in adults. *Gut*. 2008;57(1):125-136.
31. Ajmera AV, Shastri GS, Gajera MJ, Judge TA. Suboptimal response to ferrous sulfate in iron-deficient patients taking omeprazole. *Am J Ther*. 2012;19(3):185-189.
32. Maslovsky I. Intravenous iron in a primary-care clinic. *Am J Hematol*. 2005;78(4):261-264.
33. Silverstein SB, Rodgers GM. Parenteral iron therapy options. *Am J Hematol*. 2004;76(1):74-78.
34. Eichbaum Q, Foran S, Dzik S. Is iron gluconate really safer than iron dextran? *Blood*. 2003;101(9):3756-3757.
35. Murphy MF, Wallington TB, Kelsey P, et al.; British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the clinical use of red cell transfusions. *Br J Haematol*. 2001;113(1):24-31.